CircRNA6783 Inhibits Cell Proliferation and Promotes Apoptosis in Lung Adenocarcinoma.
apoptosis
circular RNA6783
lung adenocarcinoma
proliferation
Journal
Cancer management and research
ISSN: 1179-1322
Titre abrégé: Cancer Manag Res
Pays: New Zealand
ID NLM: 101512700
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
10
2021
accepted:
11
03
2022
entrez:
29
3
2022
pubmed:
30
3
2022
medline:
30
3
2022
Statut:
epublish
Résumé
Circular RNA (circRNA) serves an important role in tumour genesis and development. But, little is known about its role in lung adenocarcinoma (LA). This study aimed to investigate circRNA6783 expression in peripheral whole blood (PWB) of LA and controls and explore its effect on proliferation and apoptosis in human lung adenocarcinoma cells (LAC). The levels of circRNA6783 in LA cell lines and peripheral whole blood (PWB) of 40 patients and 30 controls were detected by real-time quantitative reverse transcription-polymerase chain reaction (RT-PCR). In order to explore the effect of circRNA6783 on LA behavior, we overexpressed circRNA6783 in NCI-H1975 cells. The impact on the proliferation of tumor cells was then examined by Cell Counting Kit 8 (CCK8) assay, and the effects on apoptosis in the cell line were detected using flow cytometry. The expression levels of circRNA6783 were significantly higher in LA cell lines and PWB (P < 0.05). The diagnostic value of the area under the receiver operating characteristic curve (AUC) was 0.830, with a sensitivity of 60% and specificity of 96.7%. In addition, functional experiments showed that overexpression of circRNA6783 restrained cell proliferation, significantly increased spontaneous apoptosis. CircRNA6783 was upregulated in LA PWB. In vitro assessment demonstrated that circRNA6783 could act as a potential biomarker for LA diagnosis.
Identifiants
pubmed: 35345604
doi: 10.2147/CMAR.S346616
pii: 346616
pmc: PMC8957399
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1229-1236Informations de copyright
© 2022 Mu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Cancer Lett. 2021 Jan 1;496:41-56
pubmed: 32931883
Mol Ther Nucleic Acids. 2020 Dec 23;23:1120-1135
pubmed: 33664993
Nat Commun. 2021 Jan 12;12(1):295
pubmed: 33436560
Oncoimmunology. 2016 Apr 22;5(5):e1138200
pubmed: 27467958
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Mol Cancer. 2021 Jan 20;20(1):19
pubmed: 33468140
Theranostics. 2021 Jan 1;11(3):1396-1411
pubmed: 33391541
Medicine (Baltimore). 2019 Oct;98(42):e17601
pubmed: 31626137
Eur Rev Med Pharmacol Sci. 2021 Jan;25(1):145-153
pubmed: 33506902
Cell Oncol (Dordr). 2021 Apr;44(2):297-310
pubmed: 33118120
Mol Cancer. 2020 Jun 29;19(1):112
pubmed: 32600329
Cell Death Dis. 2020 Jan 16;11(1):32
pubmed: 31949130
Nat Methods. 2021 Jan;18(1):51-59
pubmed: 33288960
Mol Ther Nucleic Acids. 2021 Apr 01;24:554-578
pubmed: 33981479
Cell Death Dis. 2021 Apr 19;12(5):412
pubmed: 33875646
Nat Rev Cancer. 2021 Jan;21(1):22-36
pubmed: 33082563
Transl Lung Cancer Res. 2021 Jan;10(1):57-70
pubmed: 33569293
Mol Ther Nucleic Acids. 2021 Jan 05;23:783-796
pubmed: 33614229
Front Cell Dev Biol. 2021 Jan 28;8:602707
pubmed: 33634097
Hum Cell. 2021 Mar;34(2):468-477
pubmed: 33128699
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Theranostics. 2021 Mar 12;11(11):5404-5417
pubmed: 33859754
Thorac Cancer. 2018 Aug;9(8):924-930
pubmed: 29932500
Aging (Albany NY). 2021 Jan 10;13(3):3742-3762
pubmed: 33461176
J Hepatol. 2020 Aug;73(2):371-382
pubmed: 32165252
J Thorac Oncol. 2015 Dec;10(12):1675-84
pubmed: 26709477
Mol Cancer. 2021 Jan 11;20(1):13
pubmed: 33430880
Mol Cancer. 2018 Sep 20;17(1):137
pubmed: 30236115
EMBO J. 2019 Aug 15;38(16):e100836
pubmed: 31343080